

Electronic Acknowledgement Receipt

EFS ID:	3662661
Application Number:	10501317
International Application Number:	
Confirmation Number:	6119
Title of Invention:	Cyclic urea derivatives with 5-ht2c receptor activity
First Named Inventor/Applicant Name:	Steven M Bromidge
Customer Number:	20462
Filer:	Kathryn Lutomski Sieburth/Mary Fenerty
Filer Authorized By:	Kathryn Lutomski Sieburth
Attorney Docket Number:	32969
Receipt Date:	23-JUL-2008
Filing Date:	22-FEB-2005
Time Stamp:	13:21:51
Application Type:	U.S. National Stage under 35 USC 371

Payment information:

Submitted with Payment	yes
Payment Type	Deposit Account
Payment was successfully received in RAM	\$ 930
RAM confirmation Number	10402
Deposit Account	192570
Authorized User	

The Director of the USPTO is hereby authorized to charge indicated fees and credit any overpayment as follows:

Charge any Additional Fees required under 37 C.F.R. 1.492 (National application filing, search, and examination fees)

Charge any Additional Fees required under 37 C.F.R. Section 1.17 (Patent application and reexamination processing fees)

Charge any Additional Fees required under 37 C.F.R. Section 1.19 (Document supply fees)

Charge any Additional Fees required under 37 C.F.R. Section 1.20 (Post Issuance fees)

Charge any Additional Fees required under 37 C.F.R. Section 1.21 (Miscellaneous fees and charges)

File Listing:

Document Number	Document Description	File Name	File Size(Bytes) /Message Digest	Multi Part /.zip	Pages (if appl.)
1	Request for Continued Examination (RCE)	RCE_Transmittal_Letter.pdf	83125 0d0c8537e132d5fce4463173503d5762 bf19d75ee	no	1

Warnings:

This is not a USPTO supplied RCE SB30 form.

Information:

2		Amendment_and_Extension_of_Time.pdf	369109 9d35ea1db4b301bdc4732b014a34061e 8e47d9751	yes	8
---	--	-------------------------------------	---------------------------------------------------------	-----	---

Multipart Description/PDF files in .zip description

Document Description	Start	End
Amendment - After Non-Final Rejection	1	1
Claims	2	5
Applicant Arguments/Remarks Made in an Amendment	6	8

Warnings:

Information:

3	Information Disclosure Statement Letter	Supplemental_IDS_Letter.pdf	48408 4b95596c41b54162aah422510c3754b 3961ca1e	no	1
---	-----------------------------------------	-----------------------------	------------------------------------------------------	----	---

Warnings:

Information:

4	Information Disclosure Statement (IDS) Filed	1449_Form.pdf	55654 0fbda0054ee027b67479bca29157d510 24a305d3	no	1
---	----------------------------------------------	---------------	-------------------------------------------------------	----	---

Warnings:

Information:

This is not an USPTO supplied IDS fillable form

5	Foreign Reference	1WO9404533A1.pdf	2458530 ab4b8d3d3c00addce9556025e43b78ec 4aac9f923	no	55
---	-------------------	------------------	----------------------------------------------------------	----	----

Warnings:

Information:

6	NPL Documents	3Loo_Int_Clin_Psychopharm_2002.pdf	162771 9e480cebd18696cd50a25cd249c7e4d3509707	no	9
Warnings:					
Information:					
7	NPL Documents	4Papp_Neuropsychopharmacology_2003.pdf	285453 b86d6dc930ff0e08835096a272b2b429a872238	no	10
Warnings:					
Information:					
8	NPL Documents	5Cremers_Neuropsychopharmacology_2004.pdf	185230 78b32815078d057005b74b94354c70d432025	no	8
Warnings:					
Information:					
9	NPL Documents	6Dremencov_Neuopharmacology_2005.pdf	299030 8c2b38e91a2cd750d704cd8ced9c93be30c5595c	no	9
Warnings:					
Information:					
10	NPL Documents	8OA_10511769_3_10_08.pdf	238456 1792c3397383095992a5271a5b176d39c8b78a95	no	5
Warnings:					
Information:					
11	NPL Documents	2Jenck_Exp_Opin_Invest_Drugs_1998.pdf	1343807 27a66fae24814e96ae6a13b6a70ce114d99d71c5	no	13
Warnings:					
Information:					
12	NPL Documents	7Goodacre_BOMCL_2005.pdf	373831 6d1aad3cd6b0c3cd5dfc702a3026c19ac35eb085a	no	5
Warnings:					
Information:					
13	Fee Worksheet (PTO-06)	fee-info.pdf	8340 ed47b1d994d021b1a53f05f6741e52ac45d4b789	no	2
Warnings:					
Information:					
Total Files Size (in bytes):			5911744		

This Acknowledgement Receipt evidences receipt on the noted date by the USPTO of the indicated documents, characterized by the applicant, and including page counts, where applicable. It serves as evidence of receipt similar to a Post Card, as described in MPEP 503.

New Applications Under 35 U.S.C. 111

If a new application is being filed and the application includes the necessary components for a filing date (see 37 CFR 1.53(b)-(d) and MPEP 506), a Filing Receipt (37 CFR 1.54) will be issued in due course and the date shown on this Acknowledgement Receipt will establish the filing date of the application.

National Stage of an International Application under 35 U.S.C. 371

If a timely submission to enter the national stage of an international application is compliant with the conditions of 35 U.S.C. 371 and other applicable requirements a Form PCT/DO/EO/903 indicating acceptance of the application as a national stage submission under 35 U.S.C. 371 will be issued in addition to the Filing Receipt, in due course.

New International Application Filed with the USPTO as a Receiving Office

If a new international application is being filed and the international application includes the necessary components for an international filing date (see PCT Article 11 and MPEP 1810), a Notification of the International Application Number and of the International Filing Date (Form PCT/RO/105) will be issued in due course, subject to prescriptions concerning national security, and the date shown on this Acknowledgement Receipt will establish the international filing date of the application.